Argenx upgraded to Buy at UBS on Vyvgart’s $20 bln sales potential
UBS upgraded Argenx (ARGX) to Buy with a $1,400 price target, citing Vyvgart's potential for $18B peak sales and a strong pipeline. The stock rose 2.8% in Brussels. Analyst Xian Deng highlighted better-than-expected Phase 3 data and underappreciated pipeline assets, including empasiprubart and a recent $2B acquisition.
How this was made
The 30-second read
Why it matters
The upgrade and higher target price reflect UBS’s confidence in upcoming trial readouts and a $2 bn acquisition that diversifies the pipeline.
Market read
Analyst upgrade with a sizable price target increase can trigger short‑term buying pressure and influence peer valuations.
What to watch
Potential competition in myositis and Sjögren’s disease could limit market share.
Background
Argenx (ARGX) is a European biotech focused on rare‑disease antibodies. The firm’s flagship product Vyvgart targets CIDP and is expanding into myositis and Sjögren’s disease.
Ticker impact
UBS upgraded Argenx to Buy with a new $1,400 price target, citing $20 bn peak sales potential for Vyvgart and stronger Phase 3 data.
Potential further price appreciation if sales outlook holds.
Upgrade reflects fresh clinical data and a larger sales forecast, which can attract buying pressure.
Market effects
Positive signal for biotech sector and rare‑disease therapeutics.
European biotech stocks may see modest gains.
Highlights growing demand for immunology drugs worldwide.
Counterpoint
Upgrade may be premature; Phase 3 data still carries binary risk and sales forecasts could be optimistic.
Key entities
- CompanyArgenx
Biotech developer of Vyvgart.
- AnalystUBS
Issued the upgrade and new price target.
